Trials / Not Yet Recruiting
Not Yet RecruitingNCT07527078
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Comparing the Efficacy and Safety of GZR33 Injection and Insulin Degludec Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antidiabetic Drugs
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- Sponsor
- Gan & Lee Pharmaceuticals. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.
Detailed description
This study will be conducted to evaluate the efficacy of once-daily GZR33 Injection and once-daily Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GZR33 Injection | GZR33 Injection Administered SC, once-daily |
| DRUG | Insulin Degludec Injection (Tresiba®) | Administered SC, once-daily |
Timeline
- Start date
- 2026-04-07
- Primary completion
- 2027-04-10
- Completion
- 2027-04-17
- First posted
- 2026-04-14
- Last updated
- 2026-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07527078. Inclusion in this directory is not an endorsement.